

# Future Directions in Stroke Care

Central South Regional Stroke Network  
Health Information Management Workshop  
February 17, 2022

# Objectives

- To discuss some of the future advances we might see in stroke care that can impact coding:
  - Paramedic Redirection from local Stroke Thrombolysis Centre to Endovascular Centre (Direct Access from the field)
  - Changing in thrombolysis agents
  - Expanding use of Thrombolysis for minor strokes and from 4.5 to 9.0 hours, Wake-Up Stroke or Unknown Time of Onset using CT Perfusion Software
  - Expanded use of Endovascular Therapy for a broader patient group
  - New antithrombotic agents for Stroke Prevention

## Paramedic Prompt Card for Acute Stroke Bypass Protocol

This prompt card provides a quick reference of the *Acute Stroke Protocol* contained in the *Basic Life Support Patient Care Standards (BLS PCS)*. Please refer to the BLS PCS for the full protocol.

### Indications under the Acute Stroke Protocol

Redirect or transport to the closest or most appropriate Designated Stroke Centre\* will be considered for patients who meet ALL of the following:

1. Present with a new onset of at least one of the following symptoms suggestive of the onset of an acute stroke:
  - a. Unilateral arm/leg weakness or drift.
  - b. Slurred speech or inappropriate words or mute.
  - c. Unilateral facial droop.
2. Can be transported to arrive at a Designated Stroke Centre within 6 hours of a clearly determined time of symptom onset or the time the patient was last seen in a usual state of health.
3. Perform a secondary screen for a Large Vessel Occlusion (LVO) stroke using the Los Angeles Motor Scale (LAMS) and inform the CACC/ACS to aid in the determination of the most appropriate destination.

\*A Designated Stroke Center is a Regional Stroke Centre, District Stroke Centre or a Telestroke Centre regardless of EVT capability.

### Contraindications under the Acute Stroke Protocol

ANY of the following exclude a patient from being transported under the Acute Stroke Protocol:

1. CTAS Level 1 and/or uncorrected airway, breathing or circulatory problem.
2. Symptoms of the stroke resolved prior to paramedic arrival or assessment\*\*.
3. Blood sugar <3 mmol/L\*\*\*.
4. Seizure at onset of symptoms or observed by paramedics.
5. Glasgow Coma Scale <10.
6. Terminally ill or palliative care patient.
7. Duration of out of hospital transport will exceed two hours.

\*\*Patients whose symptoms improve significantly or resolve during transport will continue to be transported to a Designated Stroke Centre.

\*\*\* If symptoms persist after correction of blood glucose level, the patient is not contraindicated.

**CACC/ACS will authorize the transport once notified of the patient's need for redirect or transport under the Acute Stroke Protocol.**

## Indications for Acute Stroke Bypass Protocol:


- Presents with new onset of at least one of the following symptoms:
  - Unilateral arm/leg weakness or drift
  - Slurred speech or inappropriate words or mute
  - Unilateral facial droop
- Can be transported to arrive at Designated Stroke Centre within 6 hours of time the patient was last seen in a usual state of health
- Perform a secondary screen for Large Vessel Occlusion (LVO) using the Los Angeles Motor Scale (LAMS)

# Los Angeles Motor Scale (LAMS) for Large Vessel Occlusion (LVO)

Step 1 Facial Droop	Step 2 Arm Drift	Step 3 Grip Strength	Step 4 Add the Score
Ask the patient to smile. <b>Is there any weakness or facial weakness?</b>	Bring the person's arms up to 90 ° angle and ask them to hold that position for 10 seconds. <b>Is there any drift or drop of arm?</b>	Ask the person to grip your hands. <b>Does one hand have less power than the other?</b>	Total Possible Score of 5  <b>A score of 4 or 5 is considered positive for Large Vessel Occlusion (LVO) and patient may benefit from Endovascular Therapy</b>
0 Absent 1 Facial Droop Present	0 Absent 1 Drips Down 2 Falls Rapidly	0 Absent 1 Weak Grip 2 No Grip	

# Central South Regional Stroke Network

## Direct Access to EVT Centre (Mothership)



# Switching from Alteplase (tPA) to Tenecteplase (tNK) for Stroke Thrombolysis

- Tenecteplase has some of the same pharmacokinetic advantages of alteplase
- Studies have been shown that TNK might be a better thrombolytic agent than tPA:
  - Non-inferior to alteplase
  - Safety outcomes were similar
  - It is easier to administer (one single bolus)
  - Less errors in dosing, less use of infusion pumps
  - May improve functional outcomes
  - Better reperfusion for large vessel occlusion strokes
  - Faster Door to EVT Suite
  - Faster DIDO times at TPA sites




# Thrombolysis with TNK for Minor Stroke with Intracranial Occlusion

- In TEMPO 1 Research Trial, TNK versus Standard of Care (antiplatelet therapy) was studied with Minor Ischemic Stroke (NIH SS  $\leq 5$ ) within 12 hours of onset of symptom onset with intracranial arterial occlusion
- This preliminary study found TNK was:
  - Feasible
  - Safe
  - Improved Functional improvement
- TEMPO 2 is an ongoing research trial to prove if the treatment is effective. Study closes 2023




# Moving from Time is Brain to Time the Brain

## Time is Brain



## Tissue Time/Time the Brain

Tissue clock/ time is brain




Wheeler HM, et al. Int J Stroke. 2015



# Expanding the Window for Thrombolysis using CT Perfusion

- Using CT Perfusion Software to select Thrombolysis for:
  - 4.5 to 9.0 Hour window
  - Wake-Up Strokes
  - Stroke with Unknown Onset time
- 3 Studies found that patients treated with alteplase versus placebo:
  - Better functional improvement
  - Slightly higher rate of symptomatic Intracranial hemorrhage but did not negate benefit of the treat




# Expanding EVT Eligibility

## Current EVT Eligibility Criteria:

- Stroke Symptoms less than 24 hours of time last seen normal
- Disabling Stroke
- Good Baseline Functioning preStroke (mRS 0 – 2)
- Large blood vessel blockage with a reachable clot
- Brain tissue that is still alive (ASPECTS  $\geq 6$ )
- Clinical Mismatch on CTP Imaging

## Expanded EVT Eligibility:

- Patients with lower ASPECTS Scores
- Patients with low NIHSS but large vessel occlusion
- Patients with tandem occlusion



# Ticagrelor Plus Aspirin for Stroke Prevention

- Thales Trial found that:
  - Patients with TIA or Minor Stroke who were treated with Ticagrelor and Aspirin had significant reduction in disabling stroke or death at 30 days and a reduced the total burden of disability to recurrent ischemic stroke at 30 days
  - Patients received a loading dose of Ticagrelor (180 mg) then a maintenance dose of 90 mg BID in addition to loading dose of 300 – 325 mg of ASA then 75 – 100 mg daily for 30 days

# Questions



Rhonda McNicoll Whiteman  
mcnicolr@hhsc.ca

# Wrap Up and Evaluation

- Workshop Evaluations:
  - You have been send a link via email to complete your evaluation
  - Please take the time to provide feedback as we use this information to inform our planning

# CME Certificate and Presentations

- Certificate for CME's:
  - After this workshop you will receive an email with the Certificate for your CME's
- Link to Presentations and Recording of the Workshop
  - You will receive an email in the next week with a link to the Workshop Presentation and Workshop Recordings on the Central South Regional Stroke Network Website

[www.csnstroke.ca](http://www.csnstroke.ca)

